...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >PTC209, a Specific Inhibitor of BMI1, Promotes Cell Cycle Arrest and Apoptosis in Cervical Cancer Cell Lines
【24h】

PTC209, a Specific Inhibitor of BMI1, Promotes Cell Cycle Arrest and Apoptosis in Cervical Cancer Cell Lines

机译:PTC209,BMI1的特异性抑制剂,促进宫颈癌细胞系中的细胞周期停滞和细胞凋亡

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background/Aim: Aberrant expression of the BMI1 oncogene has been prevalently found in a variety of human cancers, including cervical cancer. Recent studies have shown that PTC209, a specific BMI1 inhibitor, exhibits high potency in inhibiting the growth of colon, breast, oral cancer cells and cancer-initiating cells, indicative of its chemotherapeutic potential. In the current study, we evaluated the inhibitory abilities of PTC209 in cervical cancer cells. Materials and Methods: Three cervical cell lines, C33A, HeLa, and SiHa were treated with PTC209. The impacts of PTC209 on BMI1 were investigated using quantitative reverse-transcription PCR assay (qRT-PCR) and western blotting; changes in cell viability, cell cycle distribution, and apoptosis were assessed using cell viability testing, colony formation assay and flow cytometry analyses, respectively. Results: PTC209 exhibited considerably high short-term and long-term cytotoxicities in all tested cervical cancer cell lines regardless of their HPV infection status, TP53 and pRb statuses. PTC209 significantly downregulated the expression of BMI1 in cervical cancer cell lines, and such downregulation led to G0/G1 arrest (p<0.05). Moreover, PTC209 drove more cells into apoptosis (p<0.05). Conclusion: PTC209 (BMI1-targeting agents, in general) represents a novel chemotherapeutic agent with potential in cervical cancer therapy.
机译:背景/目的:BMI1癌基因的异常表达已经普遍存在各种人类癌症中,包括宫颈癌。最近的研究表明,PTC209是一种特异性BMI1抑制剂,抑制结肠,乳腺癌,口服癌细胞和癌症引发细胞的生长,表明其化学治疗潜力。在目前的研究中,我们评估了PTC209在宫颈癌细胞中的抑制能力。材料和方法:用PTC209处理三种宫颈细胞系,C33A,HELA和SIHA。使用定量反转转录PCR测定(QRT-PCR)和Western印迹研究了PTC209对BMI1的影响。使用细胞活力测试,菌落形成测定和流式细胞术分析评估细胞活力,细胞周期分布和细胞凋亡的变化。结果:无论其HPV感染状态,TP53和PRB状态如何,PTC209在所有测试的宫颈癌细胞系中表现出相当高的短期和长期细胞毒性。 PTC209显着下调BMI1在宫颈癌细胞系中的表达,这种下调导致G0 / G1停滞(P <0.05)。此外,PTC209将更多细胞驱动到细胞凋亡(P <0.05)中。结论:PTC209(BMI1靶向剂,一般)代表一种具有宫颈癌疗法潜力的新型化学治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号